http___hr.265health.com_cancer_cervical-cancer_1016014662.html_1.xml
1.1 2.1 3.1 4.1 4.2 4.3 5.1 5.2 6.1 6.2 6.3 6.4 7.1 7.2 8.1
Posts tagged Prevention 2011 EU Cervical Cancer Prevention Week0 The European Institutes of Women’s Health supports the 2011 European Cervical Cancer Prevention Week 24th-29th January 2011. Cervical cancer is the second most common cancer in women under 44 worldwide. Cervical cancer remains a serious public health problem in Europe. From the perspective of Europe as a whole, 60,000 women develop cervical cancer and 30,000 die from it every year, while the number of women living with cervical cancer (being treated or otherwise) at any one point in time in Europe is over 175,000. The prevention of cervical cancer has the potential to become a major public health success story. We should be able to lower rates of cervical cancer even further, if best practice in early detection through cancer screening and HPV vaccination programmes, were applied systematically. Progress in controlling cervical cancer has important implications for women Europe wide. “99% of cervical cancer cases are caused by persistent infection of certain high risk types of the Human Papillomavirus (HPV). HPV is the most common sexually transmitted infection in the world and approximately 50% to 80% of sexually active women contract some form of HPV at least once in their life. Only a small proportion will develop cervical cancer. Well organised screening programmes have been proven to reduce incidence of cervical cancer by 80% and the HPV vaccine has been proven almost 100% effective in preventing certain types of the virus that cause 70% of all cervical cancer cases. “(IFPA) http://www.ifpa.ie Almost all cases of cervical cancer can be prevented by screening and HPV vaccination Because the HPV vaccine does not protect against all cervical cancers, it is still vitally important for all women to have cervical screening – more commonly known as a smear test. For more information: Cervical Check
1.1 2.1 3.1 3.2 4.1 5.1 5.2 6.1 7.1 7.2 7.3 8.1 9.1 9.2 10.1 11.1 11.2 12.1
African - American žene , latino žene i Native American žene imaju veću stopu raka vrata maternice , a razvijaju komplikacije s njim nego Kavkaza žene . Raspon dobi rak grlića maternice najčešće dijagnosticira u žena u dobi između 25 i 35 godina . Obabroj slučajeva ivjerojatnost da umru od raka vrata maternice s porastom dobi . Prevalencija U 2006 bilo je preko 9700 novodijagnosticiranih slučajeva cervikalne raka u SAD-u. Učestalost bolesti ibroj smrtnih slučajeva od njega su pale u posljednjih nekoliko desetljeća , zahvaljujući češćim rano otkrivanje . Ostali faktori rizika najveća rizični faktor povezan s razvojem raka vrata maternice je HPV ,humani papiloma virus . Procjenjuje se da više od 90 posto pacijenata oboljelih od raka vrata maternice je HPV . Rizično ponašanje kao što je velik broj partnera je također povezan s rakom grlića maternice . Survival Rate stopa preživljavanja raka grlića maternice rasponima 73-92 posto . U slučajevima u kojima se nalazi rane intervencije ,stopa preživljavanja raste na više od 99 posto . Prevencija invazivnog raka vrata maternice može se spriječiti , osobito putem PAPA testa ( također poznat kao Papa testovi ) , koji je tražiti znakove raka tijekom redovite ginekološke preglede. Osim toga ,HPV cjepivo može smanjiti izglede za razvoj raka vrata maternice . From:http://hr.265health.com/cancer/cervical-cancer/1016014662.html